We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+49.92%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$124M
Cap. Flow
+$19.5M
Cap. Flow %
5.47%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$14.7M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$11.5M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$124M 34.62%
19,963,157
– –
PCVX icon
2
Vaxcyte
PCVX
$7.81B
$65.7M 18.41%
1,315,435
-141,865
-10% -$6.72M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$708M
$53.9M 15.09%
3,760,869
+1,276,595
+51% +$14.7M
MRUS
4
DELISTED
Merus
MRUS
$42.1M 11.8%
1,600,000
– –
AURA icon
5
Aura Biosciences
AURA
$725M
$37.5M 10.52%
3,039,892
– –
NAMS icon
6
NewAmsterdam Pharma
NAMS
$3.25B
$34.1M 9.56%
2,869,565
+869,565
+43% +$11.5M

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q2 2023 Portfolio in Review

As of Q2 2023, Medicxi Ventures Management held 6 positions worth $357M, up 53% from $233M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $19.5M of net new capital in Q2 2023, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vaxcyte, an estimated $6.72M trimmed.

  • Medicxi Ventures Management added most to Phathom Pharmaceuticals in Q2 2023, an estimated $14.7M increase.
  • Medicxi Ventures Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $6.72M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $357M portfolio in Q2 2023.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q2 2023.
  • Medicxi Ventures Management's portfolio value rose 53% quarter-over-quarter to $357M.

Based on Medicxi Ventures Management's 13F filing for Q2 2023, filed 19 Jul 2023.